Clinical trials: Recurrence Hepatocellular Carcinoma
Hepatocellular Carcinoma, Recurrent Cancer
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the…
- Conditions
- Hepatocellular Carcinoma, Recurrent Cancer, Liver Transplant
- Trial name
- NCT04204850
- Testing
- Cabozantinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Hepatitis B Virus, Hepatocellular Carcinoma
TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in China, and approximately 90% of the patients with HCC are also infected with hepatitis B virus (HBV).
- Trial name
- TACE (NCT00960518)
- Testing
- adefovir, TACE
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Tongji University
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HCC
Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet.
- Trial name
- ESCALATOR (NCT03097848)
- Testing
- RFA, Sorafenib
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Southwest Hospital, China
Liver Cancer
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00767468
- Testing
- sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma
Research Objective and Study End Points To evaluate the anti-HBV as well as HCC recurrence reducing effects of standard (18 months) lamivudine treatment at time of HBV reactivation with hepatitis flare up (HBV DNA > 105 copies/mL…
- Trial name
- NCT00455091
- Testing
- Adefovir Dipivoxil and Lamivudine
- Where
- 8 sites in Taiwan
- Volunteers
- 117 people
- Sponsor
- National Health Research Institutes, Taiwan
Liver Cancer
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020774
- Testing
- gemcitabine hydrochloride, lonafarnib, conventional surgery
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Hepatocellular carcinoma (HCC) recurs in up to 60% of patients who undergo resection. Circulating tumor cells (CTC) have been advocated as promotors of the recurrence.
- Conditions
- Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Circulating Tumor Cell
- Trial name
- NCT04800497
- Testing
- Hepatic resection
- Where
- 4 sites in Italy
- Volunteers
- 70 people
- Sponsor
- University of Milano Bicocca